Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug ...

WuXi Biologics agreed to sell an overseas vaccine facility to Merck & Co. for half a billion dollars, a move that could strengthen the company’s cash flow and margins as it navigates global ...

We cut our fair value estimate on narrow-moat-rated WuXi Biologics to HKD 24.60 per share from HKD 28.10 as we lower our project growth assumption for the next decade. We take a fresh look after ...

while shares of subsidiary WuXi Biologics rose nearly 15 per cent to HK$21.45. Those gains were made after Financial Times, citing people familiar with the matter, reported on Thursday that WuXi ...

WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new ...

WuXi Biologics (OTCPK:WXIBF) is reportedly selling its vaccine facility in Ireland to Merck (NYSE:MRK) as part of a previously announced plan to divest some of its assets. The China-based contract ...